小剂量利培酮强化抗抑郁剂治疗双相抑郁发作的疗效和安全性研究

doi:10.3969/j.issn.1006-7795.2014.02.013

首都医科大学学报 ›› 2014, Vol. 35 ›› Issue (2): 205-209.doi: 10.3969/j.issn.1006-7795.2014.02.013

小剂量利培酮强化抗抑郁剂治疗双相抑郁发作的疗效和安全性研究

王健, 王刚, 马辛

首都医科大学附属北京安定医院精神科, 北京 100088

收稿日期:2014-02-18 出版日期:2014-04-21 发布日期:2014-04-16
基金资助:
北京市科学技术委员会基金（D121100005012002）。

Efficacy and safety of low dosage risperidone added on valproate and citalopram in the treatment of acute bipolar depression

Wang Jian, Wang Gang, Ma Xin

Department of Psychiatry, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China

Received:2014-02-18 Online:2014-04-21 Published:2014-04-16
Contact: 马辛 E-mail:maxinanding@vip.163.com
Supported by:
This study was supported by Scientific Project of Beijing Municipal Science and Technology Commission(D121100005012002).

摘要/Abstract

摘要： 目的考察小剂量利培酮强化抗抑郁剂治疗对双相抑郁发作的疗效和安全性。方法符合入组标准的住院患者，先接受2周的丙戊酸钠（valproate，VPA）合并西酞普兰（citalopram，CIT）治疗。2周末相对于基线的蒙哥马利抑郁量表（Montgomery and Asberg Depression Scale，MADRS）减分率<50%者按照1∶1的比例采用数字表法随机分配至丙戊酸钠+西酞普兰组（VPA+CIT）或丙戊酸钠+西酞普兰+利培酮组（risperidone，RIS），接受为期6周的随机开放治疗，进行疗效评价及安全性评价。结果治疗终点VPA+CIT+RIS组和VPA+CIT组MADRS、简明精神病量表（Brief Psychiatric Rating Scale，BPRS）、临床疗效总评量表-严重程度（Clinical Global Impression-severity of illness，CGI-S）和临床疗效总评量表-改善程度（Clinical Global Impression-improvement of illness，CGI-I）评分较导入期末均明显降低，其中MADRS、BPRS 、杨氏躁狂量表（Young Mania Rating Scale，YMRS）两组对比差异没有统计学意义（P>0.05）。CGI-I 2组对比，差异具有统计学意义（P<0.05）。BPRS阳性因子评分两组对比，差异没有统计学意义（P>0.05）。随机治疗第1周末BPRS阳性因子评分VPA+CIT+RIS组较VPA+CIT组明显降低，差异有统计学意义（P<0.05），显示VPA+CIT+RIS组较VPA+CIT组在改善阳性精神病性症状方面起效更快。在随机治疗第2周，VPA+CIT+RIS组有效率为66.0%，VPA+CIT组为33.3%，显示VPA+CIT+RIS组较VPA+CIT组起效更快。结论 VPA+CIT+RIS与VPA+CIT治疗双相抑郁发作均安全有效。在快速起效及降低转相风险方面，VPA+CIT+RIS组优于VPA+CIT组。

关键词: 利培酮, 强化治疗, 双相障碍, 抑郁发作

Abstract: Objective To evaluate the augmentation efficacy and safety of low dosage risperidone, added on the usual treatment(valproate and citalopram) in the acute treatment of bipolar depression. Methods A total of 46 inpatients with a diagnostic criteria for acute depression episode with bipolar disorder according to DSM-IV-TR were first given valproate and citalopram treatment. The subjects who achieve little clinical response(i.e. reduction from baseline in total MADRS score by <50%) at the end of 2-week will enter into the randomized open-label 6-week treatment phase. The eligible subjects will be randomized to treatment with valproate & citalopram or valproate & citalopram & risperidone in a 1:1 ratio. Efficacy rating scales to be used in the study include MADRS, YMRS, BPRS(total score and positive subscale), CGI-S, and CGI-I. The evaluations of safety and tolerability include SAS, treatment-emergent mania, clinical laboratory tests, vital signs, ECG, and adverse events reports. Results At the end of treatment, the scores of MADRS, BPRS, GIC-I, and CGI-S in both treatment groups decreased significantly compared with the end of run-in period.There were statistically significant differences between groups in YMRS and CGI-I(P<0.05), but not in MADRS and BPRS(total score and positive subscale). At week 1 of randomized treatment period, the scores of BPRS positive subscale decreased sharply in the VPA+CIT+RIS group than those in the VPA+CIT group, the difference was statistically significant(P<0.05). At week 2 of randomized treatment period, the response rates of the VPA+CIT+RIS group was superior to the VPA+CIT group, the difference was statistically significant(P<0.05). It suggested that the time to response of the VPA+CIT+RIS group is shorter than that of the VPA+CIT group. Conclusion Both VPA+CIT+RIS and VPA+CIT are efficacious and well tolerated for the acute treatment of bipolar depression. For the treatment of psychosis and reducing the treatment-emergent mania, the VPA+CIT group was better than the VPA+CIT group.

Key words: resperidone, augmentation treatment, bipolar disorder, acute depressive episode

中图分类号:

R749.4

王健, 王刚, 马辛. 小剂量利培酮强化抗抑郁剂治疗双相抑郁发作的疗效和安全性研究[J]. 首都医科大学学报, 2014, 35(2): 205-209.

Wang Jian, Wang Gang, Ma Xin. Efficacy and safety of low dosage risperidone added on valproate and citalopram in the treatment of acute bipolar depression[J]. Journal of Capital Medical University, 2014, 35(2): 205-209.

参考文献

[1] Mitchell P B, Johnston A K, Frankland A, et al. Bipolar disorder in a national survey using the world mental health version of the composite international diagnostic interview: the impact of differing diagnostic algorithms[J]. Acta Psychiat Scand, 2013, 127(5):381-393.
[2] Vos T, Flaxman A D, Naghavi M, et al. Years lived with disability(YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859):2163-2196.
[3] Geddes J R, Miklowitz D J. Treatment of bipolar disorder[J]. Lancet, 2013, 381(9878):1672-1682.
[4] Hlastala S A, Frank E, Mallinger A G, et al. Bipolar depression: an underestimated treatment challenge[J]. Depress Anxiety, 1997, 5(2):73-83.
[5] Judd L L, Akiskal H S, Schettler P J, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder[J]. Arch Gen Psychiat, 2002, 59(6):530-537.
[6] Keller M B, Lavori P W, Coryell W, et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness[J]. JAMA, 1986, 255(22):3138-3142.
[7] Post R M, Denicoff K D, Leverich G S, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method[J]. J Clin Psychiat, 2003, 64(6):680-690.
[8] Kapur S, Remington G, Zipursky R B, et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study[J]. Life Sci, 1995, 57(10):L103-L107.
[9] Kapur S, Zipursky R B, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia[J]. Am J Psychiat, 1999, 156(2):286-293.
[10] Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia[J]. Am J Psychiat, 2000, 157(4):514-520.
[11] Zhang W, Perry K W, Wong D T, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex[J]. Neuropsychopharmacology, 2000, 23(3):250-262.
[12] Schatzberg A F, Cole J O, DeBattista C. Antidepressants, Manual of Clinical Psychopharmacology[M]. 4th ed. Washington DC: American Psychiatric Publishing, 2003:37-157.
[13] Dubé S, Tollefson G D, Thase M E, et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression[J]. Bipolar Disord, 2007, 9(6):618-627.
[14] Keck P E Jr, Corya S A, Altshuler L L, et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression[J]. J Clin Psychiat, 2005, 66(5):611-616.
[15] 丽苹.精神病学科的发展趋势及设想[J].解放军医药杂志, 2013, 25(3):6-10.
[16] 周小东, 付华斌, 刘知源, 等.新型抗精神病药物研发过程中面临的问题和解决方案[J].解放军医药杂志, 2012, 24(2):33-37.

小剂量利培酮强化抗抑郁剂治疗双相抑郁发作的疗效和安全性研究

Efficacy and safety of low dosage risperidone added on valproate and citalopram in the treatment of acute bipolar depression

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	刘珊珊, 房萌, 朱虹, 尹冬青, 赵燕, 赵爽, 贾竑晓. 2010年和2019年双相情感障碍住院患者的临床特征和未治疗持续时间的因素分析[J]. 首都医科大学学报, 2022, 43(3): 415-420.
[2]	罗炯, 孙丛丛, 潘伟刚, 王丹, 史晓宁, 王茜, 金文青, 梁立荣, 杨春林, 马辛, 任艳萍. 经颅交流电刺激联合抗抑郁药对抑郁发作的疗效及安全性[J]. 首都医科大学学报, 2022, 43(2): 244-248.
[3]	任艳萍, 张俊岩, 吴涵, 罗炯, 杨春林, 马辛, 姜玮. 磁惊厥治疗与无抽搐电痉挛治疗抑郁发作的早期疗效及对认知功能的影响[J]. 首都医科大学学报, 2022, 43(2): 239-243.
[4]	李晓虹, 蔡焯基, 刘敏, 王刚. 心境稳定剂单药或联合治疗对双相躁狂患者外周血单核细胞糖原合成酶激酶3活性的影响[J]. 首都医科大学学报, 2016, 37(2): 158-163.